Celon Pharma Sa · GPW:CLN
Celon Pharma Sa — Investor Presentation (October 2024)
19 slides from Celon Pharma Sa's investor presentation, October 2024
Slide 1: Company Presentation
COMPANY PRESENTATION WARSAW // 2024
Slide 2: Evolution from branded generics to innovations
Evolution from branded generics to innovations GENERICS COMPLEX GENERICS INNOVATIVE DRUG DEVELOPMENT 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 Company First generics Opening First European Upscaling Salmex Key out-licensing Esketamine PD
Slide 3: Company highlights
Company highlights • Founded in 2002 • Driven by the best people 500+ • Broad pipeline of 5 clinical stage • Footprint in >30 countries • Unique hybrid model combining employees assets and multiple identified • Diversified enabling internal positive cash flows and • Highly experienced management lea
Slide 4: Key strategic competences
Key strategic competences Various pharmaceutical Intellectual property GMP Manufacturing - Global regulatory & Full size commercial forms development management dry forms and dry supply chain infrastructure in Poland powder inhalers and global network of partnerships outside Poland Celon Pharma - Co
Slide 5: Strategic focus
Strategic focus 1 2 3 4 5 During the last 5 years, Celon is led by a strong We aim to be resource- We are building a leading We are actively seeking Celon has delivered 6 management team that and capital-efficient in innovative R&D and opportunities to partner successful data brings to the the devel
Slide 6: Led by a seasoned management team
Led by a seasoned management team Maciej Wieczorek, PhD Bartosz Szałek CEO, President of the Management Board CFO • Experienced manager in building the value of fast-growing • Founder and President of the Management Board of Celon Pharma international enterprises, who has been cooperating with priva
Slide 7: Pharma Financials
PHARMA FINANCIALS
Slide 8: Generics
Generics Q1-2024 Q1-2023 Q2-2024 Q2-2023 H1-2024 H1-2023 Change Change Change All amounts in kPLN Actual Actual Actual Actual Actual Actual Q1'24 / Q1'23 Q2'24 / Q2'23 H1'24 / H1'23 Revenues 36 318 39 314 53 572 43 215 89 889 82 529 -8% 24% 9% Revenues from sales of medicines 34 798 39 006 53 582 42
Slide 9: R&D
R&D Q1-2024 Q1-2023 Q2-2024 Q2-2023 H1-2024 H1-2023 Change Change Change All amounts in kPLN Actual Actual Actual Actual Actual Actual Q1'24 / Q1'23 Q2'24 / Q2'23 H1'24 / H1'23 Revenues 4 016 4 577 12 041 25 737 16 056 30 314 -12% -53% -47% Revenues from sales of medicines - - - - - - 0% 0% 0% Other
Slide 10: All segments
All segments Q1-2024 Q1-2023 Q2-2024 Q2-2023 H1-2024 H1-2023 Change Change Change All amounts in kPLN Actual Actual Actual Actual Actual Actual Q1'24 / Q1'23 Q2'24 / Q2'23 H1'24 / H1'23 Revenues 40 334 43 891 65 613 68 952 105 945 112 843 -8% -5% -6% Revenues from sales of medicines 34 798 39 006 53
Slide 11: Balance sheet
Balance sheet. PLN mln 30.06.2024 31 .12..2023 ASSETS 575,5 569,3 Non-current assets 368,8 379,6 A. The decrease in fixed assets as of June 30, 2024, compared to Property, plant and equipment A 287,1 298,9 Right-of-use assets 35,9 34,9 December 31, 2023, is related to the intensive capital expenditu
Slide 12: Pharma Branded Generics
PHARMA BRANDED GENERICS
Slide 13: Strong Company's generic portfolio
Strong Company's generic portfolio Salmex Zarixa Ketrel Valzek Donepex 18 000 16 000 14 000 12 000 Sales (PLN, 000) 10 000 8 000 6 000 4 000 2 000 0 08/23 09/23 10/23 11/23 12/23 01/24 02/24 03/24 04/24 05/24 06/24 07/24 08/24 Salmex 5 689 6 557 6 648 6 969 6 778 7 058 6 623 6 895 7 026 6 411 6 449
Slide 14: Pharma Innovative Business
PHARMA ININIOW NENA BUSINESS
Slide 15: Therapeutic areas
Therapeutic areas Metabolic Oncology diseases Inflamatory Neuropsychiatry diseases Celon Pharma - Company presentation 05
Slide 16: R&D centre: 46.000 m²
R&D centre: More than 350+ 46.000 m² scientists NEW: Recombinant biotech: mammalian & microbiomes Celon Pharma - Company presentation 06 Modern analytics
Slide 17: Diversified platforms drives strong pipeline
Diversified platforms drives strong pipeline CLINICAL DEVELOPMENT INDICATION MOLECULAR TARGET RESEARCH PRE-CLINICAL DEVELOPMENT PHASE I PHASE II Solid tumours FGFR Inhibitors CPL’110 Solid tumours/ haematological cancers MER Inhibitors ONCOLOGY Solid tumours Bispecific antibody targeting immune syst
Slide 18: Clinical pipeline - Key Milestones & Partnering 2024/2025
Clinical pipeline - Key Milestones & Partnering 2024/2025 Molecular Program Phase 1 Phase 2 Milestone Partnering status Target Neuropsychiatry NMDAR Agonist Falkieri Esketamine Treatment-Resistant Depression Ready to start Phase 3 Tang Capital LPP/Novohale Schizophrenia Phase 2 data completed CPL’36
Slide 19: Thank you
THANK YOU WARSAW // 2024